Optimising the duration of antibiotic therapy for ventilator-associated pneumonia

European Respiratory Review

Volumn 16, Issue 103, 2007, Pages 40-44

  Chastre, J ^a   Luyt, C E ^b  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b NONE

Author keywords

Antibiotic therapy duration; Intensive care unit; Resistance; Ventilator associated pneumonia

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; AZTREONAM; CEPHALOSPORIN DERIVATIVE; CEPHALOSPORINASE; CIPROFLOXACIN; GENTAMICIN; IMIPENEM; QUINOLONE DERIVATIVE;

ANTIBIOTIC THERAPY; HUMAN; LUNG INFECTION; MORTALITY; PSEUDOMONAS AERUGINOSA; RECURRENT INFECTION; REVIEW; RISK FACTOR; VENTILATOR ASSOCIATED PNEUMONIA;

EID: 34548181866     PISSN: 09059180     EISSN: None     Source Type: Journal    
DOI: 10.1183/09059180.00010303     Document Type: Review

References (13)

1. Wenzel RP, Sahm DF, Thornsberry C, Draghi DC, Jones ME, Karlowsky JA. In vitro susceptibilities of gram-negative bacteria isolated from hospitalized patients in four European countries, Canada, and the United States in 2000-2001 to expanded-spectrum cephalosporins and comparator antimicrobials: implications for therapy. Antimicrob Agents Chemother 2003; 47: 3089-3098.
2. Jones ME, Draghi DC, Thornsberry C, Karlowsky JA, Sahm DF, Wenzel RP. Emerging resistance among bacterial pathogens in the intensive care unit-a European and North American Surveillance study (2000-2002). Ann Clin Microbiol Antimicrob 2004; 3: 14.
3. Harbarth S, Albrich W, Goldmann DA, Huebner J. Control of multiply resistant cocci: do international comparisons help? Lancet Infect Dis 2001; 1: 251-261.
4. Neuhauser MM, Weinstein RA, Rydman R, Danziger LH, Karam G, Quinn JP. Antibiotic resistance among gramnegative bacilli in US intensive care units: implications for fluoroquinolone use. JAMA 2003; 289: 885-888.
5. Landman D, Quale JM, Mayorga D, et al. Citywide clonal outbreak of multiresistant Acinetobacter baumannii and Pseudomonas aeruginosa in Brooklyn, NY: the preantibiotic era has returned. Arch Intern Med 2002; 162: 1515-1520.
6. Dennesen PJ, van der Ven AJ, Kessels AG, Ramsay G, Bonten MJ. Resolution of infectious parameters after antimicrobial therapy in patients with ventilator-associated pneumonia. Am J Respir Crit Care Med 2001; 163: 1371-1375.
7. Chastre J, Wolff M, Fagon JY, et al. Comparison of 8 versus 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA 2003; 290: 2588-2598.
8. Ibrahim EH, Ward S, Sherman G, Schaiff R, Fraser VJ, Kollef MH. Experience with a clinical guideline for the treatment of ventilator-associated pneumonia. Crit Care Med 2001; 29: 1109-1115.
9. Combes A, Luyt CE, Fagon JY, Wolff M, Trouillet JL, Chastre J. Early predictors for infection recurrence and death in patients with ventilator-associated pneumonia. Crit Care Med 2007; 35: 146-154.
10. Micek ST, Ward S, Fraser VJ, Kollef MH. A randomized controlled trial of an antibiotic discontinuation policy for clinically suspected ventilator-associated pneumonia. Chest 2004; 125: 1791-1799.
11. Luna CM, Blanzaco D, Niederman MS, et al. Resolution of ventilator-associated pneumonia: prospective evaluation of the clinical pulmonary infection score as an early clinical predictor of outcome. Crit Care Med 2003; 31: 676-682.
12. Luyt CE, Guerin V, Combes A, et al. Procalcitonin kinetics as a prognostic marker of ventilator-associated pneumonia. Am J Respir Crit Care Med 2005; 171: 48-53.
13. American Thoracic Society; Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171: 388-416.